SUPPLEMENT

Q3 2021 — Sales of Key Products/Franchises

Q3 2021PDF · 6 pages197 KB
REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER 	NINE MONTHS
2021 	2020 	Reported 	Operational (1) 	Currency 	2021 	2020 	Reported 	Operational (1) 	Currency
CONSUMER HEALTH SEGMENT (2)
OTC
US 	686	$ 	601 	14.0% 	14.0% 	- 	1,960	$ 	1,917 	2.2% 	2.2% 	-
Intl 	686 	541 	26.9% 	22.8% 	4.1% 	1,894 	1,722 	10.0% 	3.9% 	6.1%
WW 	1,372 	1,142 	20.1% 	18.2% 	1.9% 	3,854 	3,639 	5.9% 	3.0% 	2.9%
SKIN HEALTH / BEAUTY
US 	569 	572 	-0.5% 	-0.5% 	- 	1,862 	1,767 	5.4% 	5.4% 	-
Intl 	555 	577 	-3.8% 	-5.5% 	1.7% 	1,595 	1,506 	5.9% 	2.1% 	3.8%
WW 	1,124 	1,149 	-2.2% 	-3.0% 	0.8% 	3,457 	3,273 	5.6% 	3.9% 	1.7%
ORAL CARE
US 	150 	164 	-8.4% 	-8.4% 	- 	478 	510 	-6.2% 	-6.2% 	-
Intl 	248 	248 	0.1% 	-1.8% 	1.9% 	762 	694 	9.9% 	5.9% 	4.0%
WW 	398 	412 	-3.3% 	-4.5% 	1.2% 	1,240 	1,204 	3.0% 	0.8% 	2.2%
BABY CARE
US 	95 	91 	5.2% 	5.2% 	- 	288 	279 	3.3% 	3.3% 	-
Intl 	296 	302 	-2.0% 	-3.1% 	1.1% 	879 	831 	5.8% 	4.6% 	1.2%
WW 	391 	393 	-0.3% 	-1.2% 	0.9% 	1,167 	1,110 	5.2% 	4.3% 	0.9%
WOMEN'S HEALTH
US 	3 	3 	20.1% 	20.1% 	- 	9 	10 	-5.7% 	-5.7% 	-
Intl 	229 	227 	0.5% 	0.6% 	-0.1% 	675 	654 	3.1% 	2.3% 	0.8%
WW 	232 	230 	0.8% 	0.8% 	0.0% 	684 	664 	3.0% 	2.1% 	0.9%
WOUND CARE / OTHER
US 	122 	125 	-2.6% 	-2.6% 	- 	390 	370 	5.3% 	5.3% 	-
Intl 	61 	64 	-5.2% 	-9.0% 	3.8% 	186 	175 	5.8% 	0.0% 	5.8%
WW 	182 	189 	-3.5% 	-4.8% 	1.3% 	575 	545 	5.4% 	3.6% 	1.8%
TOTAL CONSUMER HEALTH
US 	1,625 	1,556 	4.5% 	4.5% 	- 	4,987 	4,853 	2.8% 	2.8% 	-
Intl 	2,075 	1,958 	5.9% 	3.7% 	2.2% 	5,991 	5,582 	7.3% 	3.5% 	3.8%
WW 	3,700	$ 	3,514 	5.3% 	4.1% 	1.2% 	10,978	$ 	10,435 	5.2% 	3.1% 	2.1%
See footnotes at end of schedule
% Change 	% Change

-- 1 of 6 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER 	NINE MONTHS
PHARMACEUTICAL SEGMENT (2,3) 	2021 	2020 	Reported 	Operational (1) 	Currency 	2021 	2020 	Reported 	Operational (1) 	Currency
IMMUNOLOGY
US 	2,771	$ 	2,558 	8.3% 	8.3% 	- 	7,932	$ 	7,330 	8.2% 	8.2% 	-
Intl 	1,480 	1,230 	20.3% 	18.8% 	1.5% 	4,464 	3,619 	23.3% 	17.6% 	5.7%
WW 	4,250 	3,789 	12.2% 	11.7% 	0.5% 	12,395 	10,950 	13.2% 	11.3% 	1.9%
REMICADE
US 	480 	634 	-24.3% 	-24.3% 	- 	1,508 	1,852 	-18.6% 	-18.6% 	-
US Exports (4) 	47 	78 	-40.2% 	-40.2% 	- 	197 	321 	-38.7% 	-38.7% 	-
Intl 	234 	209 	12.2% 	8.1% 	4.1% 	721 	673 	7.1% 	1.4% 	5.7%
WW 	761 	921 	-17.4% 	-18.3% 	0.9% 	2,426 	2,846 	-14.8% 	-16.1% 	1.3%
SIMPONI / SIMPONI ARIA
US 	295 	312 	-5.3% 	-5.3% 	- 	840 	840 	0.0% 	0.0% 	-
Intl 	276 	280 	-1.1% 	-0.7% 	-0.4% 	877 	827 	6.1% 	2.8% 	3.3%
WW 	571 	592 	-3.3% 	-3.1% 	-0.2% 	1,717 	1,667 	3.0% 	1.4% 	1.6%
STELARA
US 	1,569 	1,313 	19.5% 	19.5% 	- 	4,396 	3,668 	19.9% 	19.9% 	-
Intl 	809 	634 	27.7% 	26.3% 	1.4% 	2,404 	1,795 	33.9% 	27.5% 	6.4%
WW 	2,378 	1,947 	22.2% 	21.7% 	0.5% 	6,800 	5,463 	24.5% 	22.4% 	2.1%
TREMFYA
US 	376 	222 	69.7% 	69.7% 	- 	975 	650 	50.1% 	50.1% 	-
Intl 	161 	105 	52.5% 	50.5% 	2.0% 	459 	316 	45.4% 	38.0% 	7.4%
WW 	537 	327 	64.1% 	63.5% 	0.6% 	1,434 	965 	48.5% 	46.1% 	2.4%
OTHER IMMUNOLOGY
US 	3 	- 	* 	* 	- 	15 	- 	* 	* 	-
Intl 	0 	3 	* 	* 	* 	3 	9 	-68.6% 	-70.8% 	2.2%
WW 	3 	3 	-26.4% 	-27.5% 	1.1% 	18 	9 	91.6% 	89.5% 	2.1%
INFECTIOUS DISEASES
US 	679 	413 	64.3% 	64.3% 	- 	1,635 	1,265 	29.2% 	29.2% 	-
Intl 	709 	451 	57.2% 	55.6% 	1.6% 	1,788 	1,397 	28.0% 	23.2% 	4.8%
WW 	1,389 	864 	60.6% 	59.8% 	0.8% 	3,424 	2,662 	28.6% 	26.1% 	2.5%
COVID-19 VACCINE
US 	270 	- 	* 	* 	- 	421 	- 	* 	* 	-
Intl 	233 	- 	* 	* 	- 	346 	- 	* 	* 	-
WW 	502 	- 	* 	* 	- 	766 	- 	* 	* 	-
EDURANT / rilpivirine
US 	12 	11 	8.4% 	8.4% 	- 	31 	33 	-4.8% 	-4.8% 	-
Intl 	247 	226 	9.7% 	8.7% 	1.0% 	733 	684 	7.2% 	1.7% 	5.5%
WW 	259 	236 	9.6% 	8.6% 	1.0% 	764 	716 	6.7% 	1.4% 	5.3%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US 	380 	379 	0.4% 	0.4% 	- 	1,128 	1,154 	-2.2% 	-2.2% 	-
Intl 	137 	147 	-7.1% 	-8.8% 	1.7% 	440 	461 	-4.6% 	-8.6% 	4.0%
WW 	517 	526 	-1.7% 	-2.2% 	0.5% 	1,568 	1,615 	-2.9% 	-4.1% 	1.2%
OTHER INFECTIOUS DISEASES
US 	18 	24 	-26.0% 	-26.0% 	- 	55 	79 	-29.6% 	-29.6% 	-
Intl 	93 	78 	18.3% 	15.2% 	3.1% 	270 	252 	6.9% 	2.6% 	4.3%
WW 	110 	102 	7.8% 	5.4% 	2.4% 	325 	331 	-1.8% 	-5.0% 	3.2%
% Change 	% Change

-- 2 of 6 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER 	NINE MONTHS
2021 	2020 	Reported 	Operational (1) 	Currency 	2021 	2020 	Reported 	Operational (1) 	Currency
NEUROSCIENCE
US 	835 	759 	10.2% 	10.2% 	- 	2,448 	2,285 	7.2% 	7.2% 	-
Intl 	854 	846 	0.8% 	-0.5% 	1.3% 	2,770 	2,565 	8.0% 	4.1% 	3.9%
WW 	1,689 	1,605 	5.3% 	4.6% 	0.7% 	5,218 	4,850 	7.6% 	5.5% 	2.1%
CONCERTA / Methylphenidate
US 	35 	43 	-19.5% 	-19.5% 	- 	117 	150 	-22.1% 	-22.1% 	-
Intl 	122 	107 	14.2% 	12.5% 	1.7% 	372 	319 	16.4% 	11.6% 	4.8%
WW 	157 	149 	4.5% 	3.3% 	1.2% 	489 	469 	4.1% 	0.8% 	3.3%
INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA
US 	648 	585 	11.0% 	11.0% 	- 	1,882 	1,704 	10.4% 	10.4% 	-
Intl 	355 	341 	4.3% 	3.2% 	1.1% 	1,111 	983 	13.0% 	7.6% 	5.4%
WW 	1,004 	926 	8.5% 	8.1% 	0.4% 	2,994 	2,688 	11.4% 	9.4% 	2.0%
RISPERDAL CONSTA
US 	71 	70 	1.3% 	1.3% 	- 	210 	220 	-4.7% 	-4.7% 	-
Intl 	69 	81 	-16.7% 	-16.0% 	-0.7% 	242 	254 	-5.1% 	-8.3% 	3.2%
WW 	140 	152 	-8.4% 	-8.0% 	-0.4% 	452 	475 	-4.9% 	-6.6% 	1.7%
OTHER NEUROSCIENCE
US 	81 	60 	34.7% 	34.7% 	- 	239 	210 	13.9% 	13.9% 	-
Intl 	307 	317 	-2.9% 	-4.8% 	1.9% 	1,045 	1,008 	3.7% 	1.5% 	2.2%
WW 	388 	377 	3.1% 	1.5% 	1.6% 	1,284 	1,218 	5.5% 	3.6% 	1.9%
ONCOLOGY
US 	1,525 	1,267 	20.3% 	20.3% 	- 	4,364 	3,623 	20.4% 	20.4% 	-
Intl 	2,140 	1,862 	14.9% 	13.8% 	1.1% 	6,406 	5,310 	20.6% 	15.3% 	5.3%
WW 	3,665 	3,129 	17.1% 	16.5% 	0.6% 	10,770 	8,933 	20.6% 	17.4% 	3.2%
DARZALEX
US 	841 	585 	43.7% 	43.7% 	- 	2,302 	1,540 	49.5% 	49.5% 	-
Intl 	739 	514 	43.7% 	42.0% 	1.7% 	2,076 	1,397 	48.6% 	42.2% 	6.4%
WW 	1,580 	1,099 	43.7% 	42.9% 	0.8% 	4,378 	2,937 	49.1% 	46.0% 	3.1%
ERLEADA
US 	214 	152 	40.5% 	40.5% 	- 	578 	407 	41.8% 	41.8% 	-
Intl 	130 	55 	* 	* 	* 	329 	112 	* 	* 	*
WW 	344 	206 	66.7% 	65.8% 	0.9% 	907 	519 	74.7% 	72.2% 	2.5%
IMBRUVICA
US 	413 	450 	-8.3% 	-8.3% 	- 	1,311 	1,329 	-1.3% 	-1.3% 	-
Intl 	654 	581 	12.6% 	10.9% 	1.7% 	1,996 	1,682 	18.7% 	13.1% 	5.6%
WW 	1,066 	1,031 	3.5% 	2.5% 	1.0% 	3,307 	3,011 	9.9% 	6.7% 	3.2%
ZYTIGA / abiraterone acetate
US 	25 	58 	-57.0% 	-57.0% 	- 	96 	284 	-66.2% 	-66.2% 	-
Intl 	523 	532 	-1.8% 	-2.1% 	0.3% 	1,653 	1,564 	5.7% 	0.9% 	4.8%
WW 	548 	590 	-7.2% 	-7.5% 	0.3% 	1,749 	1,848 	-5.4% 	-9.4% 	4.0%
OTHER ONCOLOGY
US 	32 	21 	49.6% 	49.6% 	- 	76 	63 	21.0% 	21.0% 	-
Intl 	94 	181 	-48.0% 	-47.2% 	-0.8% 	352 	556 	-36.6% 	-38.5% 	1.9%
WW 	126 	203 	-37.6% 	-36.9% 	-0.7% 	428 	619 	-30.7% 	-32.4% 	1.7%
% Change 	% Change

-- 3 of 6 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER 	NINE MONTHS
2021 	2020 	Reported 	Operational (1) 	Currency 	2021 	2020 	Reported 	Operational (1) 	Currency
PULMONARY HYPERTENSION
US 	610 	510 	19.7% 	19.7% 	- 	1,778 	1,541 	15.4% 	15.4% 	-
Intl 	258 	239 	7.9% 	8.4% 	-0.5% 	821 	742 	10.7% 	7.3% 	3.4%
WW 	868 	749 	15.9% 	16.1% 	-0.2% 	2,599 	2,283 	13.9% 	12.7% 	1.2%
OPSUMIT
US 	299 	244 	22.8% 	22.8% 	- 	861 	729 	18.2% 	18.2% 	-
Intl 	159 	148 	7.4% 	7.8% 	-0.4% 	510 	458 	11.3% 	7.7% 	3.6%
WW 	458 	392 	17.0% 	17.1% 	-0.1% 	1,371 	1,187 	15.5% 	14.1% 	1.4%
UPTRAVI
US 	265 	226 	17.3% 	17.3% 	- 	792 	692 	14.6% 	14.6% 	-
Intl 	44 	34 	30.4% 	28.8% 	1.6% 	135 	100 	34.6% 	27.9% 	6.7%
WW 	309 	260 	19.0% 	18.8% 	0.2% 	927 	792 	17.1% 	16.2% 	0.9%
OTHER PULMONARY HYPERTENSION
US 	47 	40 	14.4% 	14.4% 	- 	125 	121 	2.8% 	2.8% 	-
Intl 	54 	57 	-4.4% 	-2.1% 	-2.3% 	176 	183 	-3.7% 	-5.0% 	1.3%
WW 	101 	97 	3.4% 	4.8% 	-1.4% 	301 	304 	-1.1% 	-1.9% 	0.8%
CARDIOVASCULAR / METABOLISM / OTHER
US 	800 	931 	-14.0% 	-14.0% 	- 	2,379 	2,574 	-7.6% 	-7.6% 	-
Intl 	333 	351 	-5.1% 	-8.2% 	3.1% 	1,007 	1,052 	-4.2% 	-9.3% 	5.1%
WW 	1,133 	1,281 	-11.5% 	-12.4% 	0.9% 	3,386 	3,625 	-6.6% 	-8.1% 	1.5%
XARELTO
US 	636 	630 	0.8% 	0.8% 	- 	1,794 	1,716 	4.5% 	4.5% 	-
Intl 	- 	- 	- 	- 	- 	- 	- 	- 	- 	-
WW 	636 	630 	0.8% 	0.8% 	- 	1,794 	1,716 	4.5% 	4.5% 	-
INVOKANA / INVOKAMET
US 	66 	156 	-57.4% 	-57.4% 	- 	249 	405 	-38.4% 	-38.4% 	-
Intl 	67 	68 	-1.0% 	-4.3% 	3.3% 	194 	173 	11.9% 	5.8% 	6.1%
WW 	133 	224 	-40.3% 	-41.3% 	1.0% 	443 	578 	-23.4% 	-25.2% 	1.8%
PROCRIT / EPREX
US 	47 	69 	-30.9% 	-30.9% 	- 	168 	215 	-21.7% 	-21.7% 	-
Intl 	65 	63 	3.1% 	0.5% 	2.6% 	198 	208 	-4.7% 	-9.7% 	5.0%
WW 	112 	132 	-14.6% 	-15.8% 	1.2% 	366 	423 	-13.4% 	-15.8% 	2.4%
OTHER
US 	51 	75 	-32.6% 	-32.6% 	- 	168 	238 	-29.3% 	-29.3% 	-
Intl 	200 	219 	-8.7% 	-11.9% 	3.2% 	615 	670 	-8.3% 	-13.1% 	4.8%
WW 	251 	294 	-14.8% 	-17.2% 	2.4% 	783 	908 	-13.8% 	-17.3% 	3.5%
TOTAL PHARMACEUTICAL
US 	7,221 	6,438 	12.2% 	12.2% 	- 	20,536 	18,619 	10.3% 	10.3% 	-
Intl 	5,773 	4,980 	15.9% 	14.6% 	1.3% 	17,256 	14,685 	17.5% 	12.5% 	5.0%
WW 	12,994	$ 	11,418 	13.8% 	13.2% 	0.6% 	37,792	$ 	33,304 	13.5% 	11.3% 	2.2%
% Change 	% Change

-- 4 of 6 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER 	NINE MONTHS
MEDICAL DEVICES SEGMENT (2) 	2021 	2020 	Reported 	Operational (1) 	Currency 	2021 	2020 	Reported 	Operational (1) 	Currency
INTERVENTIONAL SOLUTIONS
US 	444	$ 	399 	11.1% 	11.1% 	- 	1,353 	1,019 	32.7% 	32.7% 	-
Intl 	513 	437 	17.7% 	15.1% 	2.6% 	1,599 	1,134 	41.1% 	34.3% 	6.8%
WW 	957 	836 	14.5% 	13.2% 	1.3% 	2,952 	2,153 	37.1% 	33.6% 	3.5%
ORTHOPAEDICS
US 	1,249 	1,308 	-4.5% 	-4.5% 	- 	3,821 	3,427 	11.5% 	11.5% 	-
Intl 	843 	774 	8.8% 	6.8% 	2.0% 	2,611 	2,145 	21.7% 	15.4% 	6.3%
WW 	2,093 	2,083 	0.5% 	-0.3% 	0.8% 	6,433 	5,572 	15.4% 	13.0% 	2.4%
HIPS
US 	210 	221 	-5.3% 	-5.3% 	- 	654 	564 	15.9% 	15.9% 	-
Intl 	146 	124 	18.8% 	16.0% 	2.8% 	451 	344 	31.3% 	24.1% 	7.2%
WW 	356 	345 	3.3% 	2.3% 	1.0% 	1,105 	908 	21.8% 	19.0% 	2.8%
KNEES
US 	184 	205 	-9.8% 	-9.8% 	- 	579 	527 	10.0% 	10.0% 	-
Intl 	131 	102 	28.1% 	25.9% 	2.2% 	403 	298 	35.4% 	28.2% 	7.2%
WW 	316 	308 	2.8% 	2.1% 	0.7% 	983 	825 	19.2% 	16.6% 	2.6%
TRAUMA
US 	455 	433 	5.3% 	5.3% 	- 	1,352 	1,194 	13.3% 	13.3% 	-
Intl 	260 	253 	2.4% 	0.9% 	1.5% 	805 	698 	15.2% 	9.5% 	5.7%
WW 	715 	685 	4.2% 	3.7% 	0.5% 	2,157 	1,892 	14.0% 	11.9% 	2.1%
SPINE, SPORTS & OTHER
US 	400 	449 	-11.1% 	-11.1% 	- 	1,236 	1,142 	8.2% 	8.2% 	-
Intl 	306 	295 	3.5% 	1.5% 	2.0% 	952 	805 	18.2% 	12.0% 	6.2%
WW 	705 	745 	-5.3% 	-6.1% 	0.8% 	2,187 	1,947 	12.3% 	9.7% 	2.6%
% Change 	% Change

-- 5 of 6 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER 	NINE MONTHS
2021 	2020 	Reported 	Operational (1) 	Currency 	2021 	2020 	Reported 	Operational (1) 	Currency
SURGERY
US 	948 	913 	3.9% 	3.9% 	- 	2,881 	2,247 	28.2% 	28.2% 	-
Intl 	1,457 	1,239 	17.6% 	14.8% 	2.8% 	4,418 	3,556 	24.2% 	18.4% 	5.8%
WW 	2,405 	2,152 	11.8% 	10.2% 	1.6% 	7,299 	5,803 	25.8% 	22.2% 	3.6%
ADVANCED
US 	440 	421 	4.6% 	4.6% 	- 	1,304 	1,079 	20.9% 	20.9% 	-
Intl 	705 	579 	21.8% 	18.4% 	3.4% 	2,126 	1,644 	29.3% 	23.1% 	6.2%
WW 	1,144 	1,000 	14.6% 	12.6% 	2.0% 	3,430 	2,723 	26.0% 	22.2% 	3.8%
GENERAL
US 	508 	492 	3.3% 	3.3% 	- 	1,577 	1,168 	35.0% 	35.0% 	-
Intl 	752 	660 	13.9% 	11.7% 	2.2% 	2,292 	1,912 	19.9% 	14.5% 	5.4%
WW 	1,261 	1,152 	9.4% 	8.1% 	1.3% 	3,869 	3,080 	25.6% 	22.3% 	3.3%
VISION
US 	475 	473 	0.6% 	0.6% 	- 	1,414 	1,160 	21.9% 	21.9% 	-
Intl 	714 	608 	17.4% 	17.4% 	0.0% 	2,103 	1,683 	25.0% 	22.0% 	3.0%
WW 	1,189 	1,081 	10.1% 	10.0% 	0.1% 	3,517 	2,843 	23.7% 	22.0% 	1.7%
CONTACT LENSES / OTHER
US 	359 	375 	-4.3% 	-4.3% 	- 	1,082 	924 	17.0% 	17.0% 	-
Intl 	522 	455 	14.9% 	15.2% 	-0.3% 	1,525 	1,274 	19.8% 	17.3% 	2.5%
WW 	882 	830 	6.2% 	6.4% 	-0.2% 	2,607 	2,198 	18.6% 	17.2% 	1.4%
SURGICAL
US 	117 	98 	19.6% 	19.6% 	- 	333 	236 	41.1% 	41.1% 	-
Intl 	191 	153 	24.7% 	23.7% 	1.0% 	577 	409 	41.1% 	36.7% 	4.4%
WW 	308 	251 	22.7% 	22.1% 	0.6% 	910 	645 	41.1% 	38.3% 	2.8%
TOTAL MEDICAL DEVICES
US 	3,117 	3,092 	0.8% 	0.8% 	- 	9,470 	7,852 	20.6% 	20.6% 	-
Intl 	3,527 	3,058 	15.4% 	13.3% 	2.1% 	10,731 	8,518 	26.0% 	20.5% 	5.5%
WW 	6,644	$ 	6,150 	8.0% 	7.0% 	1.0% 	20,201	$ 	16,370 	23.4% 	20.5% 	2.9%
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Certain prior year amounts have been reclassified to conform to current year product disclosures
(4) Reported as U.S. sales
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and,
therefore, may not recalculate precisely.
% Change 	% Change

-- 6 of 6 --